Tumor News and Research

RSS

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

On September 18, 2013, a surgical team at Temple University Hospital, Philadelphia, Pa., performed a groundbreaking procedure on a patient who had previously been diagnosed with inoperable metastatic Stage 4 Breast cancer, using the Canady Vieira Hybrid Plasma Scalpel developed and sold by US Medical Innovations, LLC.

25 Oct 2013

Rice University research reveals 3-way genetic switch for cancer metastasis

Cancer researchers from Rice University have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch's dynamics also allows a third choice that lies somewhere between "on" and "off." The extra setting both explains previously confusing experimental results and opens the door to new avenues of cancer treatment.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Gene-diet interaction may shed light on increased risk of colorectal cancer linked with meat consumption

A newly discovered potential gene-diet interaction for colorectal cancer was reported today (Thursday, Oct. 24) at the American Society of Human Genetics 2013 meeting in Boston.

25 Oct 2013

Scientists identify link between rare mutations in RINT1 gene and early onset breast cancer risk

An international team of scientists has identified an association between heritable, rare mutations in the RINT1 gene and increased risk of early onset breast cancer, according to research reported today (Oct. 24) at the American Society of Human Genetics 2013 annual meeting in Boston.

25 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

Study identifies gene that raises risk for colorectal cancer from eating red or processed meat

A common genetic variant that affects 1 in 3 people significantly increases the risk of colorectal cancer from the consumption of red meat and processed meat, according to a study presented today at the annual American Society of Human Genetics 2013 meeting, the largest gathering of human geneticists in the world.

25 Oct 2013

Amedica signs distribution agreement with K2M

Amedica Corporation, a biomaterial company, announced today that it has entered into a distribution agreement with K2M that will provide surgeons and hospitals in Europe with access to Amedica's Silicon Nitride interbody spinal fusion devices.

24 Oct 2013

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting.

24 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

IBM joins with University Hospital Zurich to test new prototype tool for diagnosing cancer

IBM scientists are collaborating with pathologists at the University Hospital Zurich to test a new prototype tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

23 Oct 2013

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

23 Oct 2013

P400 predicts RCC outcome

Reduced expression of a senescence-associated protein is associated with worse outcome in patients with renal cell carcinoma, study findings show.

22 Oct 2013

Tumor News and Research

MIT researchers design stealth drug delivery system to attack TNBC cells

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

Rice University research reveals 3-way genetic switch for cancer metastasis

"One-two punch" disables tumors' defenses

Gene-diet interaction may shed light on increased risk of colorectal cancer linked with meat consumption

Scientists identify link between rare mutations in RINT1 gene and early onset breast cancer risk

Study: Investigational drug shows promise against pancreatic cancer

Study identifies gene that raises risk for colorectal cancer from eating red or processed meat

Amedica signs distribution agreement with K2M

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

IBM joins with University Hospital Zurich to test new prototype tool for diagnosing cancer

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

P400 predicts RCC outcome

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News